Search Results
Search results for "Design Pharmaceuticals"
Results found for "Design Pharmaceuticals"
- Lab Leadership Without Ego: How Sokhom Pin Built the Happiest Team at Alkermes
empowerment , not micromanagement He hired based on attitude and team fit , not just credentials He designed
- Radioligands vs. Fluorescent Ligands: Binding Assays
. -Â Â Â Â Â Â Â Â Â Â Â Fluorescent probe design for specific targets: Â Not all targets have available high-affinity If you are curious about fluorescent probes, fluorescent probe design or GPCR tools, feel free to contact
- The Hidden Operating Cadence That’s Actually Driving Your Biotech
uncomfortable truth: 👉 Your biotech is already running on an operating cadence you didn’t consciously design They drift because their cadence isn’t designed.
- How System-Level GPCR Thinking Prevents Discovery Failures
Johannes Broichhagen explains how next-generation fluorescent probes—designed with precise synthetic His work shows why chemical design can outperform antibodies and how rigorous assay validation bridges
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
chemical structure of the lead compounds to improve potency and selectivity, thereby optimising the drug's design Furthermore, understanding these resistance mechanisms enables the design of next-generation drugs that It also helps in combination therapy strategies, where drugs are designed to target multiple sites or
- GPCR Internalization: When the Signal Moves Inside the Cell
This framework shaped how assays were designed, how drug candidates were profiled, and how efficacy was BRET-based assays can quantify beta-arrestin recruitment and, depending on the assay design, distinguish
- Innovative Data-Driven Solutions: The pHSense Revolution
Instead of creating another black-box assay, they designed pHSense around rare-earth europium probes. The Chemistry That Almost Didn’t Work Designing pH-sensitive rare-earth complexes was not an obvious
- GPCR Drug Discovery at Discovery on Target: Why This Track Is About More Than Receptors
Structure-based design  powered by cryo-EM and AI. 🔬 Inside the GPCR Track Agenda Expect deep dives is more than an academic experience — it’s like being handed a new set of tools to rethink your drug design
- Purpose-Driven Opioid Research: Catherine Demery’s Academic Path
It’s about finding purpose through loss, choosing academia when many peers walk away, and designing science potencies in seized samples, drug combinations that mirror contamination patterns, and experimental designs
- New Podcast, Sweet Structures & $2.2B GPCR Moves
Rock your favorite design, spark conversations in the lab, and help power everything we build—one mug
- Artificial intelligence – faster, smarter, cheaper GPCR drug discovery
discovery has the potential to accelerate the identification and development of novel drugs, optimize drug design compared; and 3) detection, prediction, or generation (e.g. prediction of a protein structure, or ligand design De novo drug design: AI algorithms can generate new molecules with desired properties, such as binding Multi-target drug design: GPCRs are often involved in complex signaling networks. With the revolution of biased signalling of GPCRs comes the possibility of designing drugs that selectively
- Four Reasons to Measure GPCR Signaling Bias in Drug Discovery
As different ligands stabilize different receptor conformations, it is possible to design molecules that Rather than abandoning a target because of a harmful pathway, bias offers a different answer: design A biased ligand can be designed to favor pathways.
- Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling
Some innovative solutions have been the development of the BERKY and the ONE-GO biosensors, designed The ONE-GO biosensors, designed in a single vector, incorporate a G protein tagged with a YFP acceptor M., et al., Revealing the Activity of Trimeric G-proteins in Live Cells with a Versatile Biosensor Design
- Decoding Olfactory GPCRs: How AlphaFold and AI Are Changing the Game
That meant simulations, ligand screening, and experimental design could move forward with confidence.
- Dr. GPCR and Eurofins Discovery Join Forces to Advance GPCR Drug Discovery
services with an engaged global community of GPCR researchers, and the scientific context that helps teams design
- From Lab Logic to Leadership: How Scientific Thinking Holds Back Biotech Operations
Startups Play by Different Rules — and Most Scientific Founders Miss That  A research lab is designed A startup is designed for progress.
- A Note from Yamina: Building the Next Chapter of Dr. GPCR
GPCR Foundry  — our R&D and biotech hub designed to bridge GPCR science with execution. The Dr. GPCR Retreat  — our largest in-person event yet, designed to bring together scientists, industry leaders
- How Advanced GPCR Kinetics Sharpen Decision Making (and Save You Time)
orphan GPCR strategies; and advances across nanodiscs, peptidiscs, SMALPs, SPR, ITC—plus how construct design Members-only networking, AMAs & matchmaking 💡 Support open resources for the global GPCR field 🧠Designed
- Mechanistic basis of GPCR activation explored by ensemble refinement of crystallographic structures
crystallography and cryo-EM have resulted in a wealth of GPCR structures that have been used in drug design
- GPCR News Flash! Top Updates You Can't-Miss! + University CheatSheet is finally available! âť„ Dec 2 - 8, 2024
Structure-guided design of a peripherally restricted chemogenetic system Hye Jin Kang , Brian E Krumm effective in relapsed myeloma after CAR T-cell therapy Methods & Updates in GPCR Research Structure-guided design
- Function and structure of bradykinin receptor 2 for drug discovery
molecular insights into the functions and regulation of B2R, which shed light on structure-based drug design
- Advantages of Fluorescent Probes in GPCR Assays
Thus, rational design using efficient synthetic strategies is needed to make these probes as specific Our scientific team can guide you choose or design the right fluorescent ligand for your research. Â
- Molecular insights into psychedelic drug action
With the United States Food and Drug Administration's designation of psilocybin as a "Breakthrough Therapy
- Structural basis of GPCR coupling to distinct signal transducers: implications for biased signaling
do not reveal a clear conformational basis for signaling bias, which would have enabled the rational design
- Understanding Orthosteric Binding: The Key to Drug Action
It can inform decisions in drug design, improving therapeutic outcomes and reducing unwanted side effects
- Chemogenetic stimulation of the G i pathway in astrocytes suppresses neuroinflammation
Engineered G protein-coupled receptors (GPCRs) are commonly used in chemogenetics as designer receptors exclusively activated by designer drugs (DREADDs).
- Opioid Ligands Addressing Unconventional Binding Sites and More Than One Opioid Receptor Subtype
side effects, and tools to explore the ORs nature and function, various (poly)pharmacological ligand design
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Tirzepatide's success underscores the potential of designing drugs that selectively target beneficial basis of biased agonism continues to grow, it is likely to play an increasingly important role in the design
- Structural insights into adhesion GPCR ADGRL3 activation and Gq, Gs, Gi, and G12 coupling
A detailed analysis of the engagements allows us to design mutations that specifically enhance one pathway
- Community guidelines for GPCR ligand bias: IUPHAR review 32
Here, we provide guidelines and terminology for any scientists to design and report ligand bias experiments



















